A study of Sacubatril/valsartan in improving prognosis of uremia patients with heart failure on peritoneal dialysis

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100043953

Enrollment

Unknown

Registered

2021-03-06

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uremia peritoneal dialysis with heart failure

Interventions

Case series:Sacubatril/valsartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The age is over 18 years old; 2. Long-term continuous peritoneal dialysis; 3. The cardiac function NYHA classification (NYHA grade II - IV); 4. Good compliance and regular outpatient follow-up; 5. Agree to participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Basal blood pressure continuously under 90/60mmHg; 2. Severe liver function impairment: the Child grade of liver function was C; Decompensated cirrhosis; Biliary cirrhosis and cholestasis; 3. Allergic to the active ingredients of this product (shakubactral, valsartan) or any excipients; 4. Angieurotic edema after previous use of ACEI or ARB drugs; 5. Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
NT-proBNP;Echocardiogram;Number of hospitalizations;Medical expenses;short form 36 questionnaire;subjective nutrition assessment;	—

Countries

China

Contacts

Public ContactTian Na

Department of Nephrology, General Hospital of Ningxia Medical University

snowwife@163.com+86 18095173735

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026